piperacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, 6-aminopenicillanic acid derivatives | 2187 | 61477-96-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 14 | g | P |
| 14 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 714.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 71 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 772.85 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.27 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.96 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 29, 1981 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sepsis | 102.44 | 18.36 | 120 | 9348 | 153003 | 63326551 |
| Pyrexia | 100.48 | 18.36 | 218 | 9250 | 470260 | 63009294 |
| Thrombocytopenia | 97.04 | 18.36 | 116 | 9352 | 151041 | 63328513 |
| Toxic epidermal necrolysis | 93.54 | 18.36 | 54 | 9414 | 25280 | 63454274 |
| Acute kidney injury | 75.19 | 18.36 | 138 | 9330 | 263277 | 63216277 |
| Rash maculo-papular | 72.49 | 18.36 | 50 | 9418 | 31846 | 63447708 |
| Respiratory failure | 68.32 | 18.36 | 80 | 9388 | 101778 | 63377776 |
| Septic shock | 65.30 | 18.36 | 64 | 9404 | 66565 | 63412989 |
| Multiple organ dysfunction syndrome | 64.17 | 18.36 | 59 | 9409 | 56693 | 63422861 |
| Pancytopenia | 61.49 | 18.36 | 74 | 9394 | 96859 | 63382695 |
| Renal failure | 56.11 | 18.36 | 78 | 9390 | 117574 | 63361980 |
| Disseminated intravascular coagulation | 55.79 | 18.36 | 35 | 9433 | 19016 | 63460538 |
| Fatigue | 54.10 | 18.36 | 33 | 9435 | 887995 | 62591559 |
| Eosinophilia | 52.47 | 18.36 | 36 | 9432 | 22720 | 63456834 |
| Platelet count decreased | 50.96 | 18.36 | 74 | 9394 | 116048 | 63363506 |
| Excessive eye blinking | 50.67 | 18.36 | 15 | 9453 | 1265 | 63478289 |
| Dermatitis exfoliative generalised | 48.29 | 18.36 | 19 | 9449 | 3788 | 63475766 |
| Drug reaction with eosinophilia and systemic symptoms | 47.92 | 18.36 | 40 | 9428 | 33796 | 63445758 |
| Urinary tract obstruction | 46.48 | 18.36 | 16 | 9452 | 2192 | 63477362 |
| Tubulointerstitial nephritis | 44.74 | 18.36 | 31 | 9437 | 19872 | 63459682 |
| Leukopenia | 42.58 | 18.36 | 55 | 9413 | 77235 | 63402319 |
| Arthralgia | 40.85 | 18.36 | 17 | 9451 | 569693 | 62909861 |
| Tonic clonic movements | 40.61 | 18.36 | 13 | 9455 | 1422 | 63478132 |
| Pseudomembranous colitis | 37.61 | 18.36 | 15 | 9453 | 3097 | 63476457 |
| Febrile neutropenia | 37.47 | 18.36 | 65 | 9403 | 118384 | 63361170 |
| Blood creatinine increased | 37.10 | 18.36 | 55 | 9413 | 87789 | 63391765 |
| Rash morbilliform | 36.65 | 18.36 | 15 | 9453 | 3310 | 63476244 |
| Drug ineffective | 35.31 | 18.36 | 64 | 9404 | 1044701 | 62434853 |
| Haemoglobin decreased | 35.00 | 18.36 | 71 | 9397 | 145414 | 63334140 |
| Joint swelling | 34.96 | 18.36 | 4 | 9464 | 327662 | 63151892 |
| Drug intolerance | 34.94 | 18.36 | 3 | 9465 | 308658 | 63170896 |
| Headache | 33.87 | 18.36 | 27 | 9441 | 633214 | 62846340 |
| Haemolytic anaemia | 33.20 | 18.36 | 20 | 9448 | 10105 | 63469449 |
| Biloma | 32.40 | 18.36 | 6 | 9462 | 61 | 63479493 |
| Heparin-induced thrombocytopenia | 32.03 | 18.36 | 15 | 9453 | 4567 | 63474987 |
| Alopecia | 31.68 | 18.36 | 6 | 9462 | 337530 | 63142024 |
| Stevens-Johnson syndrome | 30.26 | 18.36 | 27 | 9441 | 24923 | 63454631 |
| Agranulocytosis | 30.09 | 18.36 | 27 | 9441 | 25107 | 63454447 |
| Abdominal discomfort | 29.49 | 18.36 | 6 | 9462 | 320879 | 63158675 |
| Acute generalised exanthematous pustulosis | 29.04 | 18.36 | 19 | 9449 | 11080 | 63468474 |
| Hepatic function abnormal | 27.96 | 18.36 | 31 | 9437 | 37111 | 63442443 |
| Haemophagocytic lymphohistiocytosis | 27.34 | 18.36 | 18 | 9450 | 10609 | 63468945 |
| Transplant rejection | 27.10 | 18.36 | 18 | 9450 | 10762 | 63468792 |
| Nephropathy toxic | 26.71 | 18.36 | 17 | 9451 | 9462 | 63470092 |
| Peripheral swelling | 26.55 | 18.36 | 4 | 9464 | 265938 | 63213616 |
| Neutropenia | 26.26 | 18.36 | 71 | 9397 | 174934 | 63304620 |
| Dizziness | 26.03 | 18.36 | 16 | 9452 | 429909 | 63049645 |
| Pleural effusion | 25.45 | 18.36 | 48 | 9420 | 93162 | 63386392 |
| Linear IgA disease | 24.77 | 18.36 | 9 | 9459 | 1442 | 63478112 |
| Product dose omission issue | 24.63 | 18.36 | 3 | 9465 | 234310 | 63245244 |
| Anaemia | 24.12 | 18.36 | 97 | 9371 | 293333 | 63186221 |
| Aspergillus infection | 24.02 | 18.36 | 15 | 9453 | 8078 | 63471476 |
| Leukocytosis | 23.70 | 18.36 | 24 | 9444 | 25911 | 63453643 |
| Autoimmune haemolytic anaemia | 23.03 | 18.36 | 12 | 9456 | 4589 | 63474965 |
| Hypokalaemia | 23.00 | 18.36 | 49 | 9419 | 103755 | 63375799 |
| Ejection fraction decreased | 22.88 | 18.36 | 22 | 9446 | 22310 | 63457244 |
| Weight increased | 21.74 | 18.36 | 6 | 9462 | 260786 | 63218768 |
| Prothrombin time prolonged | 21.73 | 18.36 | 15 | 9453 | 9549 | 63470005 |
| Unresponsive to stimuli | 21.71 | 18.36 | 26 | 9442 | 33790 | 63445764 |
| Platelet count increased | 21.15 | 18.36 | 19 | 9449 | 17692 | 63461862 |
| Product contamination microbial | 20.19 | 18.36 | 5 | 9463 | 214 | 63479340 |
| Hypotension | 19.96 | 18.36 | 87 | 9381 | 272517 | 63207037 |
| Fall | 19.38 | 18.36 | 18 | 9450 | 392316 | 63087238 |
| Systemic lupus erythematosus | 18.98 | 18.36 | 4 | 9464 | 208914 | 63270640 |
| Cytarabine syndrome | 18.85 | 18.36 | 4 | 9464 | 85 | 63479469 |
| Small intestinal obstruction | 18.67 | 18.36 | 18 | 9450 | 18319 | 63461235 |
| Epidermolysis | 18.59 | 18.36 | 6 | 9462 | 673 | 63478881 |
| Large intestine perforation | 18.56 | 18.36 | 13 | 9455 | 8469 | 63471085 |
| Mental status changes | 18.47 | 18.36 | 26 | 9442 | 39573 | 63439981 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis | 105.10 | 15.58 | 74 | 12024 | 20950 | 34923883 |
| Acute kidney injury | 100.99 | 15.58 | 281 | 11817 | 304707 | 34640126 |
| Thrombocytopenia | 94.87 | 15.58 | 183 | 11915 | 156064 | 34788769 |
| Sepsis | 78.68 | 15.58 | 176 | 11922 | 166385 | 34778448 |
| Pyrexia | 77.85 | 15.58 | 272 | 11826 | 332741 | 34612092 |
| Drug reaction with eosinophilia and systemic symptoms | 72.12 | 15.58 | 72 | 12026 | 32940 | 34911893 |
| Cholestasis | 53.80 | 15.58 | 56 | 12042 | 26892 | 34917941 |
| Eosinophilia | 51.47 | 15.58 | 54 | 12044 | 26168 | 34918665 |
| Rash maculo-papular | 49.54 | 15.58 | 55 | 12043 | 28396 | 34916437 |
| Disseminated intravascular coagulation | 48.40 | 15.58 | 48 | 12050 | 21768 | 34923065 |
| Multiple organ dysfunction syndrome | 46.71 | 15.58 | 90 | 12008 | 76476 | 34868357 |
| Clostridial infection | 45.16 | 15.58 | 23 | 12075 | 3604 | 34941229 |
| Toxic epidermal necrolysis | 43.23 | 15.58 | 45 | 12053 | 21601 | 34923232 |
| Renal tubular necrosis | 41.43 | 15.58 | 38 | 12060 | 15642 | 34929191 |
| Agranulocytosis | 41.38 | 15.58 | 46 | 12052 | 23775 | 34921058 |
| Neutropenia | 40.76 | 15.58 | 133 | 11965 | 156645 | 34788188 |
| Rash | 40.30 | 15.58 | 168 | 11930 | 222584 | 34722249 |
| Septic shock | 39.67 | 15.58 | 81 | 12017 | 71753 | 34873080 |
| Dizziness | 36.51 | 15.58 | 15 | 12083 | 218506 | 34726327 |
| Renal failure | 35.96 | 15.58 | 113 | 11985 | 130444 | 34814389 |
| Respiratory failure | 34.64 | 15.58 | 99 | 11999 | 108473 | 34836360 |
| Stevens-Johnson syndrome | 34.12 | 15.58 | 37 | 12061 | 18602 | 34926231 |
| Choroiditis | 32.03 | 15.58 | 13 | 12085 | 1202 | 34943631 |
| Heparin-induced thrombocytopenia | 31.01 | 15.58 | 21 | 12077 | 5574 | 34939259 |
| Gamma-glutamyltransferase increased | 30.85 | 15.58 | 44 | 12054 | 29187 | 34915646 |
| Fatigue | 30.49 | 15.58 | 51 | 12047 | 370602 | 34574231 |
| Clostridium difficile colitis | 30.15 | 15.58 | 32 | 12066 | 15698 | 34929135 |
| Blood alkaline phosphatase increased | 30.10 | 15.58 | 45 | 12053 | 31130 | 34913703 |
| Congenital pneumonia | 30.07 | 15.58 | 7 | 12091 | 95 | 34944738 |
| Nephropathy toxic | 28.48 | 15.58 | 28 | 12070 | 12560 | 34932273 |
| Death | 28.14 | 15.58 | 60 | 12038 | 397989 | 34546844 |
| Blood creatinine increased | 26.86 | 15.58 | 83 | 12015 | 94893 | 34849940 |
| Pancytopenia | 26.76 | 15.58 | 83 | 12015 | 95074 | 34849759 |
| Febrile neutropenia | 25.30 | 15.58 | 104 | 11994 | 136745 | 34808088 |
| Autoimmune haemolytic anaemia | 25.22 | 15.58 | 17 | 12081 | 4479 | 34940354 |
| Alanine aminotransferase increased | 25.09 | 15.58 | 73 | 12025 | 80742 | 34864091 |
| Arthralgia | 24.83 | 15.58 | 14 | 12084 | 170027 | 34774806 |
| Blood bilirubin increased | 24.54 | 15.58 | 46 | 12052 | 38250 | 34906583 |
| Aspartate aminotransferase increased | 23.76 | 15.58 | 64 | 12034 | 67719 | 34877114 |
| Transplant rejection | 23.44 | 15.58 | 23 | 12075 | 10288 | 34934545 |
| Pneumonia staphylococcal | 23.36 | 15.58 | 14 | 12084 | 3010 | 34941823 |
| Subclavian artery occlusion | 23.36 | 15.58 | 6 | 12092 | 125 | 34944708 |
| Nephritis | 23.34 | 15.58 | 13 | 12085 | 2438 | 34942395 |
| Acute respiratory distress syndrome | 22.98 | 15.58 | 36 | 12062 | 25933 | 34918900 |
| Hepatic failure | 22.78 | 15.58 | 42 | 12056 | 34489 | 34910344 |
| Chondritis | 21.81 | 15.58 | 6 | 12092 | 164 | 34944669 |
| Device related infection | 21.28 | 15.58 | 28 | 12070 | 17209 | 34927624 |
| Rash erythematous | 21.23 | 15.58 | 34 | 12064 | 24943 | 34919890 |
| Haemodialysis | 21.22 | 15.58 | 22 | 12076 | 10504 | 34934329 |
| Skin exfoliation | 20.19 | 15.58 | 35 | 12063 | 27397 | 34917436 |
| Dialysis | 20.07 | 15.58 | 22 | 12076 | 11186 | 34933647 |
| Weight increased | 19.89 | 15.58 | 4 | 12094 | 93029 | 34851804 |
| Organ failure | 19.66 | 15.58 | 11 | 12087 | 2080 | 34942753 |
| Drug eruption | 19.60 | 15.58 | 29 | 12069 | 19869 | 34924964 |
| Interstitial lung disease | 19.33 | 15.58 | 58 | 12040 | 65224 | 34879609 |
| Headache | 18.98 | 15.58 | 25 | 12073 | 200610 | 34744223 |
| Hepatic function abnormal | 18.78 | 15.58 | 45 | 12053 | 44318 | 34900515 |
| Weight decreased | 18.78 | 15.58 | 20 | 12078 | 176281 | 34768552 |
| Anaphylactic reaction | 18.49 | 15.58 | 37 | 12061 | 32264 | 34912569 |
| Platelet count decreased | 18.32 | 15.58 | 86 | 12012 | 119631 | 34825202 |
| Leukopenia | 17.82 | 15.58 | 55 | 12043 | 62801 | 34882032 |
| Petechiae | 17.77 | 15.58 | 19 | 12079 | 9399 | 34935434 |
| Dermatitis exfoliative | 17.36 | 15.58 | 16 | 12082 | 6623 | 34938210 |
| Hepatic cytolysis | 17.05 | 15.58 | 23 | 12075 | 14473 | 34930360 |
| Abdominal abscess | 17.01 | 15.58 | 13 | 12085 | 4162 | 34940671 |
| Renal impairment | 16.80 | 15.58 | 71 | 12027 | 94442 | 34850391 |
| Blister | 16.60 | 15.58 | 29 | 12069 | 22829 | 34922004 |
| Muscle spasms | 16.51 | 15.58 | 3 | 12095 | 74998 | 34869835 |
| Antibiotic level below therapeutic | 16.23 | 15.58 | 4 | 12094 | 70 | 34944763 |
| Intraocular pressure increased | 16.11 | 15.58 | 14 | 12084 | 5369 | 34939464 |
| Respiratory distress | 15.99 | 15.58 | 37 | 12061 | 35628 | 34909205 |
| Hypotension | 15.94 | 15.58 | 131 | 11967 | 221518 | 34723315 |
| Scar pain | 15.92 | 15.58 | 4 | 12094 | 76 | 34944757 |
| Neuralgic amyotrophy | 15.63 | 15.58 | 5 | 12093 | 232 | 34944601 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 162.67 | 16.11 | 362 | 17812 | 519042 | 79207172 |
| Thrombocytopenia | 148.10 | 16.11 | 237 | 17937 | 265022 | 79461192 |
| Pyrexia | 146.17 | 16.11 | 410 | 17764 | 678299 | 79047915 |
| Sepsis | 138.60 | 16.11 | 232 | 17942 | 269196 | 79457018 |
| Tubulointerstitial nephritis | 138.48 | 16.11 | 94 | 18080 | 38141 | 79688073 |
| Toxic epidermal necrolysis | 116.66 | 16.11 | 90 | 18084 | 44491 | 79681723 |
| Drug reaction with eosinophilia and systemic symptoms | 112.80 | 16.11 | 103 | 18071 | 64141 | 79662073 |
| Rash maculo-papular | 102.55 | 16.11 | 92 | 18082 | 55986 | 79670228 |
| Septic shock | 96.39 | 16.11 | 129 | 18045 | 122672 | 79603542 |
| Eosinophilia | 88.10 | 16.11 | 77 | 18097 | 45268 | 79680946 |
| Renal failure | 82.56 | 16.11 | 157 | 18017 | 200811 | 79525403 |
| Multiple organ dysfunction syndrome | 80.45 | 16.11 | 117 | 18057 | 120129 | 79606085 |
| Fatigue | 79.40 | 16.11 | 58 | 18116 | 929669 | 78796545 |
| Pancytopenia | 67.44 | 16.11 | 129 | 18045 | 165616 | 79560598 |
| Arthralgia | 66.02 | 16.11 | 24 | 18150 | 571779 | 79154435 |
| Disseminated intravascular coagulation | 65.90 | 16.11 | 59 | 18115 | 35783 | 79690431 |
| Respiratory failure | 64.23 | 16.11 | 133 | 18041 | 180778 | 79545436 |
| Dizziness | 59.25 | 16.11 | 23 | 18151 | 526418 | 79199796 |
| Clostridial infection | 59.23 | 16.11 | 28 | 18146 | 5686 | 79720528 |
| Agranulocytosis | 58.06 | 16.11 | 61 | 18113 | 44969 | 79681245 |
| Heparin-induced thrombocytopenia | 55.81 | 16.11 | 32 | 18142 | 9650 | 79716564 |
| Transplant rejection | 54.70 | 16.11 | 41 | 18133 | 19396 | 79706818 |
| Platelet count decreased | 54.33 | 16.11 | 130 | 18044 | 194534 | 79531680 |
| Stevens-Johnson syndrome | 52.18 | 16.11 | 54 | 18120 | 39112 | 79687102 |
| Autoimmune haemolytic anaemia | 51.82 | 16.11 | 29 | 18145 | 8351 | 79717863 |
| Headache | 51.63 | 16.11 | 44 | 18130 | 653728 | 79072486 |
| Nephropathy toxic | 50.74 | 16.11 | 40 | 18134 | 20379 | 79705835 |
| Joint swelling | 50.69 | 16.11 | 4 | 18170 | 288642 | 79437572 |
| Neutropenia | 50.35 | 16.11 | 162 | 18012 | 287548 | 79438666 |
| Cholestasis | 49.13 | 16.11 | 60 | 18114 | 52049 | 79674165 |
| Renal tubular necrosis | 47.58 | 16.11 | 42 | 18132 | 24997 | 79701217 |
| Febrile neutropenia | 46.87 | 16.11 | 137 | 18037 | 230862 | 79495352 |
| Peripheral swelling | 46.61 | 16.11 | 4 | 18170 | 269613 | 79456601 |
| Product dose omission issue | 44.69 | 16.11 | 3 | 18171 | 247534 | 79478680 |
| Weight increased | 43.18 | 16.11 | 6 | 18168 | 277380 | 79448834 |
| Leukopenia | 42.90 | 16.11 | 87 | 18087 | 116426 | 79609788 |
| Urinary tract obstruction | 42.30 | 16.11 | 21 | 18153 | 4744 | 79721470 |
| Acute generalised exanthematous pustulosis | 41.16 | 16.11 | 33 | 18141 | 17221 | 79708993 |
| Nasopharyngitis | 40.69 | 16.11 | 5 | 18169 | 253876 | 79472338 |
| Clostridium difficile colitis | 40.31 | 16.11 | 43 | 18131 | 32240 | 79693974 |
| Pseudomembranous colitis | 39.91 | 16.11 | 21 | 18153 | 5353 | 79720861 |
| Blood creatinine increased | 39.48 | 16.11 | 100 | 18074 | 154957 | 79571257 |
| Alopecia | 38.48 | 16.11 | 4 | 18170 | 231351 | 79494863 |
| Drug intolerance | 38.21 | 16.11 | 7 | 18167 | 264112 | 79462102 |
| Rash | 37.18 | 16.11 | 242 | 17932 | 578116 | 79148098 |
| Fall | 37.03 | 16.11 | 34 | 18140 | 487595 | 79238619 |
| Excessive eye blinking | 36.61 | 16.11 | 14 | 18160 | 1687 | 79724527 |
| Dialysis | 35.14 | 16.11 | 31 | 18143 | 18431 | 79707783 |
| Abdominal discomfort | 33.48 | 16.11 | 8 | 18166 | 250719 | 79475495 |
| Acute respiratory distress syndrome | 32.57 | 16.11 | 45 | 18129 | 44022 | 79682192 |
| Choroiditis | 32.01 | 16.11 | 12 | 18162 | 1369 | 79724845 |
| Dermatitis exfoliative generalised | 31.56 | 16.11 | 20 | 18154 | 7221 | 79718993 |
| Weight decreased | 30.39 | 16.11 | 22 | 18152 | 355176 | 79371038 |
| Nephritis | 29.98 | 16.11 | 16 | 18158 | 4198 | 79722016 |
| Prothrombin time prolonged | 29.45 | 16.11 | 27 | 18147 | 16872 | 79709342 |
| Drug ineffective | 29.29 | 16.11 | 137 | 18037 | 1080776 | 78645438 |
| Hypotension | 28.71 | 16.11 | 185 | 17989 | 440132 | 79286082 |
| Hepatic function abnormal | 28.59 | 16.11 | 56 | 18118 | 73051 | 79653163 |
| Staphylococcal sepsis | 28.57 | 16.11 | 25 | 18149 | 14701 | 79711513 |
| Petechiae | 28.56 | 16.11 | 29 | 18145 | 20536 | 79705678 |
| Haemoglobin decreased | 28.47 | 16.11 | 113 | 18061 | 222006 | 79504208 |
| Renal impairment | 27.69 | 16.11 | 89 | 18085 | 157694 | 79568520 |
| Haemolytic anaemia | 26.35 | 16.11 | 26 | 18148 | 17794 | 79708420 |
| Tonic clonic movements | 26.28 | 16.11 | 12 | 18162 | 2252 | 79723962 |
| Rash erythematous | 26.01 | 16.11 | 47 | 18127 | 57722 | 79668492 |
| Interstitial lung disease | 25.96 | 16.11 | 70 | 18104 | 112530 | 79613684 |
| Intravascular haemolysis | 25.95 | 16.11 | 9 | 18165 | 821 | 79725393 |
| Haemodialysis | 25.92 | 16.11 | 26 | 18148 | 18142 | 79708072 |
| Linear IgA disease | 25.45 | 16.11 | 13 | 18161 | 3119 | 79723095 |
| Enterococcal infection | 25.32 | 16.11 | 24 | 18150 | 15636 | 79710578 |
| Hepatic failure | 25.30 | 16.11 | 48 | 18126 | 61164 | 79665050 |
| Blood alkaline phosphatase increased | 25.18 | 16.11 | 49 | 18125 | 63615 | 79662599 |
| Biloma | 24.77 | 16.11 | 6 | 18168 | 151 | 79726063 |
| Pain in extremity | 24.71 | 16.11 | 28 | 18146 | 364510 | 79361704 |
| Musculoskeletal stiffness | 24.54 | 16.11 | 5 | 18169 | 175003 | 79551211 |
| Rash morbilliform | 24.37 | 16.11 | 16 | 18158 | 6134 | 79720080 |
| Drug abuse | 24.20 | 16.11 | 4 | 18170 | 162687 | 79563527 |
| Subclavian artery occlusion | 24.16 | 16.11 | 6 | 18168 | 168 | 79726046 |
| Aspartate aminotransferase increased | 24.14 | 16.11 | 78 | 18096 | 138563 | 79587651 |
| Clostridium difficile infection | 23.53 | 16.11 | 38 | 18136 | 42647 | 79683567 |
| Aplasia pure red cell | 23.15 | 16.11 | 17 | 18157 | 7793 | 79718421 |
| Antibiotic level above therapeutic | 23.05 | 16.11 | 8 | 18166 | 732 | 79725482 |
| Leukocytosis | 23.02 | 16.11 | 38 | 18136 | 43417 | 79682797 |
| Aspergillus infection | 23.00 | 16.11 | 25 | 18149 | 19136 | 79707078 |
| Pleural effusion | 22.87 | 16.11 | 79 | 18095 | 145183 | 79581031 |
| Antibiotic level below therapeutic | 22.67 | 16.11 | 5 | 18169 | 82 | 79726132 |
| Blood bilirubin increased | 22.65 | 16.11 | 48 | 18126 | 66184 | 79660030 |
| Dermatitis exfoliative | 22.26 | 16.11 | 19 | 18155 | 10810 | 79715404 |
| Encephalopathy | 22.08 | 16.11 | 48 | 18126 | 67349 | 79658865 |
| White blood cell count increased | 22.04 | 16.11 | 51 | 18123 | 74582 | 79651632 |
| Staphylococcal infection | 22.00 | 16.11 | 44 | 18130 | 58251 | 79667963 |
| Respiratory distress | 21.98 | 16.11 | 44 | 18130 | 58295 | 79667919 |
| Renal injury | 21.93 | 16.11 | 23 | 18151 | 16904 | 79709310 |
| Swelling | 21.91 | 16.11 | 11 | 18163 | 216700 | 79509514 |
| Pneumonia | 21.81 | 16.11 | 238 | 17936 | 660008 | 79066206 |
| Skin exfoliation | 21.29 | 16.11 | 42 | 18132 | 55058 | 79671156 |
| Insomnia | 21.20 | 16.11 | 15 | 18159 | 245155 | 79481059 |
| Pain | 20.95 | 16.11 | 86 | 18088 | 703716 | 79022498 |
| Neutrophilic dermatosis | 20.80 | 16.11 | 7 | 18167 | 583 | 79725631 |
| Systemic candida | 20.79 | 16.11 | 15 | 18159 | 6691 | 79719523 |
| Muscle spasms | 20.68 | 16.11 | 7 | 18167 | 174723 | 79551491 |
| Inappropriate schedule of product administration | 20.52 | 16.11 | 3 | 18171 | 133625 | 79592589 |
| Hepatic cytolysis | 20.47 | 16.11 | 28 | 18146 | 27123 | 79699091 |
| Haemophagocytic lymphohistiocytosis | 20.34 | 16.11 | 25 | 18149 | 21812 | 79704402 |
| Immune effector cell-associated neurotoxicity syndrome | 20.26 | 16.11 | 14 | 18160 | 5834 | 79720380 |
| Alanine aminotransferase increased | 20.25 | 16.11 | 82 | 18092 | 162488 | 79563726 |
| Toxic skin eruption | 19.93 | 16.11 | 25 | 18149 | 22268 | 79703946 |
| Pathogen resistance | 19.50 | 16.11 | 20 | 18154 | 14322 | 79711892 |
| Chondritis | 19.49 | 16.11 | 5 | 18169 | 160 | 79726054 |
| Toxicity to various agents | 19.40 | 16.11 | 42 | 18132 | 421498 | 79304716 |
| Contusion | 19.36 | 16.11 | 5 | 18169 | 148771 | 79577443 |
| Mixed liver injury | 19.16 | 16.11 | 15 | 18159 | 7563 | 79718651 |
| Depression | 19.09 | 16.11 | 13 | 18161 | 216777 | 79509437 |
| Extravasation blood | 18.87 | 16.11 | 6 | 18168 | 418 | 79725796 |
| Neutrophil count decreased | 18.33 | 16.11 | 55 | 18119 | 93904 | 79632310 |
| Sinusitis | 18.20 | 16.11 | 11 | 18163 | 195490 | 79530724 |
| Acanthosis | 17.91 | 16.11 | 6 | 18168 | 493 | 79725721 |
| Pneumonia pseudomonal | 17.82 | 16.11 | 13 | 18161 | 5898 | 79720316 |
| Abdominal abscess | 17.78 | 16.11 | 14 | 18160 | 7113 | 79719101 |
| Blood culture positive | 17.75 | 16.11 | 15 | 18159 | 8414 | 79717800 |
| Pneumonia staphylococcal | 17.67 | 16.11 | 12 | 18162 | 4862 | 79721352 |
| Purpura | 17.62 | 16.11 | 22 | 18152 | 19505 | 79706709 |
| Injection site pain | 17.60 | 16.11 | 4 | 18170 | 129834 | 79596380 |
| Drug eruption | 17.59 | 16.11 | 34 | 18140 | 43901 | 79682313 |
| Oliguria | 17.38 | 16.11 | 20 | 18154 | 16289 | 79709925 |
| Anaphylactic reaction | 17.27 | 16.11 | 50 | 18124 | 83693 | 79642521 |
| Organ failure | 17.23 | 16.11 | 11 | 18163 | 4022 | 79722192 |
| Hepatocellular injury | 16.87 | 16.11 | 35 | 18139 | 47558 | 79678656 |
| Gamma-glutamyltransferase increased | 16.85 | 16.11 | 38 | 18136 | 54642 | 79671572 |
| Mental status changes | 16.83 | 16.11 | 43 | 18131 | 66916 | 79659298 |
| White blood cell count decreased | 16.75 | 16.11 | 86 | 18088 | 188202 | 79538012 |
| Neuralgic amyotrophy | 16.70 | 16.11 | 5 | 18169 | 285 | 79725929 |
| Hyperbilirubinaemia | 16.58 | 16.11 | 24 | 18150 | 24494 | 79701720 |
| Cytarabine syndrome | 16.46 | 16.11 | 4 | 18170 | 102 | 79726112 |
| Skin oedema | 16.43 | 16.11 | 8 | 18166 | 1733 | 79724481 |
| Malaise | 16.41 | 16.11 | 57 | 18117 | 489812 | 79236402 |
| Chronic hepatitis C | 16.33 | 16.11 | 6 | 18168 | 647 | 79725567 |
| Bone marrow failure | 16.29 | 16.11 | 36 | 18138 | 51071 | 79675143 |
| Gait disturbance | 16.28 | 16.11 | 14 | 18160 | 207492 | 79518722 |
| Feeling abnormal | 16.21 | 16.11 | 8 | 18166 | 159191 | 79567023 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CA12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Penicillins with extended spectrum |
| ATC | J01CR05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Combinations of penicillins, incl. beta-lactamase inhibitors |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Septicemia due to Escherichia coli | indication | 9323009 | |
| Bacterial septicemia | indication | 10001005 | DOID:0040085 |
| Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Streptococcal septicemia | indication | 29577008 | |
| Acute gonococcal urethritis | indication | 29864006 | |
| Postoperative infection | indication | 33910007 | |
| Pneumonia due to Pseudomonas | indication | 41381004 | |
| Peritonitis | indication | 48661000 | |
| Lower respiratory tract infection | indication | 50417007 | |
| Pneumonia due to Escherichia coli | indication | 51530003 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Klebsiella cystitis | indication | 60867007 | |
| Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Infection due to Escherichia coli | indication | 71057007 | |
| Bacterial infection due to Serratia | indication | 71120004 | |
| Rhinoscleroma | indication | 72409005 | DOID:11336 |
| Appendicitis | indication | 74400008 | DOID:8337 |
| Abdominal abscess | indication | 75100008 | |
| Septicemia due to Bacteroides | indication | 79587009 | |
| Septicemia due to Serratia | indication | 82091000 | |
| Infection of bone | indication | 111253001 | |
| Female genital tract infection | indication | 125585007 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Infection due to Enterobacteriaceae | indication | 128945009 | |
| Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
| Proteus septicemia | indication | 300986008 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Septicemia due to enterococcus | indication | 310669007 | |
| Infectious disorder of joint | indication | 363162000 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Nosocomial pneumonia | indication | 425464007 | |
| Sepsis due to Pseudomonas | indication | 448813005 | |
| Sepsis due to Gram negative bacteria | indication | 449082003 | |
| Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
| Skin and Skin Structure Bacteroides Fragilis Infection | indication | ||
| E. Coli Appendicitis | indication | ||
| Bacteroides Pneumonia | indication | ||
| Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
| Bacteroides Peritonitis | indication | ||
| Skin and Skin Structure Enterococcus Infection | indication | ||
| Prevention of Perioperative Infection | indication | ||
| Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
| Bacteroides Pelvic Inflammatory Disease | indication | ||
| Bacteroides Pelvic Cellulitis | indication | ||
| Bacteroides Endometritis | indication | ||
| E. Coli Peritonitis | indication | ||
| Pseudomonas Aeruginosa Joint Infection | indication | ||
| Bacteroides Complicated Appendicitis | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| E. Coli Pelvic Inflammatory Disease | indication | ||
| Skin and Skin Structure Serratia Infection | indication | ||
| Bacteroides Appendicitis | indication | ||
| Neisseria Gonorrhea Pelvic Cellulitis | indication | ||
| Enterococcus Peritonitis | indication | ||
| Cesarean Section Infection Prevention | indication | ||
| Vaginal Hysterectomy Infection Prevention | indication | ||
| Enterococcus Pelvic Inflammatory Disease | indication | ||
| Bacteroides Osteomyelitis | indication | ||
| Infection Prevention for GI Surgery | indication | ||
| Enterococcus Joint Infection | indication | ||
| Clostridium Peritonitis | indication | ||
| Complicated Skin and Skin Structure Infection | indication | ||
| Inflammatory Disease of Female Pelvic Organs | indication | ||
| Pseudomonas Aeruginosa Osteomyelitis | indication | ||
| Peptostreptococcus Pelvic Inflammatory Disease | indication | ||
| Complicated Proteus UTI | indication | ||
| Staphylococcus Nosocomial Pneumonia | indication | ||
| Skin and Skin Structure Acinetobacter Infection | indication | ||
| Bacteroides Joint Infection | indication | ||
| Enterococcus Complicated UTI | indication | ||
| Skin and Skin Structure Proteus Infection | indication | ||
| Enterobacter Pneumonia | indication | ||
| E. Coli Complicated Appendicitis | indication | ||
| E. Coli Endometritis | indication | ||
| Diabetic Foot Infection | indication | ||
| Enterococcus Osteomyelitis | indication | ||
| Enterococcus Endometritis | indication | ||
| Complicated UTI with Pseudomonas Aeruginosa | indication | ||
| Skin and Skin Structure Pseudomonas Aeruginosa Infection | indication | ||
| Enterococcus Pelvic Cellulitis | indication | ||
| Ecthyma gangrenosum | off-label use | 17732003 | |
| Sepsis of the newborn | off-label use | 206376005 | |
| Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
| Pseudomonas Respiratory Tract Infection in Cystic Fibrosis | off-label use | ||
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.79 | acidic |
| pKa2 | 12.64 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 40MG BASE/ML;EQ 5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 40MG BASE/ML;EQ 5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK | |||||||
| Beta-lactamase | Enzyme | Ki | 6.70 | CHEMBL | |||||
| Streptokinase A | Enzyme | EC50 | 6.55 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019896 | VUID |
| N0000147981 | NUI |
| D00466 | KEGG_DRUG |
| 59703-84-3 | SECONDARY_CAS_RN |
| 4018917 | VANDF |
| 4019896 | VANDF |
| C0031955 | UMLSCUI |
| CHEBI:8232 | CHEBI |
| WPP | PDB_CHEM_ID |
| CHEMBL702 | ChEMBL_ID |
| CHEMBL1200820 | ChEMBL_ID |
| D010878 | MESH_DESCRIPTOR_UI |
| DB00319 | DRUGBANK_ID |
| 10921 | IUPHAR_LIGAND_ID |
| X00B0D5O0E | UNII |
| 43672 | PUBCHEM_CID |
| 203134 | RXNORM |
| 1514 | MMSL |
| 5304 | MMSL |
| 60235 | MMSL |
| d00057 | MMSL |
| 002688 | NDDF |
| 004832 | NDDF |
| 11644000 | SNOMEDCT_US |
| 372836004 | SNOMEDCT_US |
| 74575000 | SNOMEDCT_US |
| 66258-76-2 | SECONDARY_CAS_RN |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 27 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9632 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 29 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9636 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 29 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9638 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 29 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 12 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 12 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 12 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 26 sections |